Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME(TM)) in the mouse

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 3, 1999, Pages 271-277

  Sandberg, Jennifer A ^a   Bouhana, Karyn S ^a   Gallegos, Anna M ^a   Agrawal, Arun B ^a   Grimm, Susan L ^a   Wincott, Francine E ^a   Reynolds, Mark A ^a   Pavco, Pamela A ^a   Parry, Tom J ^a  

^a Sirna Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FEMUR; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032800329     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1999.9.271     Document Type: Article

References (13)

1. AGRAWAL, S., TEMSAMANI, J., GALBRAITH, W., and TANG, J.Y. (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
2. BEIGELMAN, L., McSWIGGEN, J.A., DRAPER, K.G., GONZALEZ, C., JENSEN, K., KARPEISKY, A., MODAK, A.S., MATULIC-ADAMIC, J., DIRENZO, A.B., HAEBERLI, P., SWEEDLER, D., TRACZ, D., GRIMM, S., WINCOTT, F.E., THACKRAY, V.G., and USMAN, N. (1995). Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. 270, 25702-25708.
3. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
4. DESJARDINS, J.P., SPROAT, B.S., BEIJER, B., BLASCHKE, M., DUNKEL, M., GERDES, W., LUDWIG, J., REITHER, V., RUPP, T., and IVERSEN, P.L. (1996). Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther. 278, 1419-1427.
5. FLORY, C.M., PAVCO, P.A., JARVIS, T.C., LESCH, M.E., WINCOTT, P.E., BEIGELMAN, L., HUNT, S.W. 3rd and SCHRIER, D.J. (1996). Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci. USA 93, 754-758.
6. LYNGSTADAAS, S.P., RISNES, S., SPROAT, B.S., THRANE, P.S., and PRYDZ, H.P. (1995). A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 14, 5224-5229.
7. NATIONAL RESEARCH COUNCIL. (1996). Guide for the Care and Use of Laboratory Animals. (National Academy Press, Washington, DC).
8. OEFNER, P.J., HUBER, G.G., UMLAUFT, F., BERTI, G.-N., STIMPFL E., and BONN, G.K. (1994). High-resolution liquid chromatography of fluorescent dye-labeled nucleic acids. Anal. Biochem. 223, 9-46.
9. PHILLIPS, J.A., CRAIG, S.J., BAYLEY, D., CHRISTIAN, R.A., GEARY, R., and NICKLIN, P.L. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657-668.
10. SAIJO, Y., PERLAKY L., WANG, H., and BUSCH, H. (1994). Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6, 243-249.
11. SIOUD, M., and SØRENSEN, D.R. (1998). A nuclease-resistant protein kinase Cα ribozyme blocks glioma eel growth. Nature Biotechnol 16, 556-561.
12. USMAN, N., and STINCHCOMB, D.T. (1996). Design, synthesis and function of therapeutic hammerhead ribozymes. Nucleic Acids Mol. Biol. 10, 243-264.
13. WINCOTT, F., DIRIENZO, A., SHAFFER, C., GRIMM, S., TRACZ, D., WORKMAN, C., SWEEDLER, D., GONZALEZ, C., SCARINGE, S., and USMAN, N. (1995). Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucl Acid. Res. 23(14), 2677-2684.